VJHemOnc is committed to improving our service to you

BSH 2018 | Combination therapies in CLL: ibrutinib and venetoclax

VJHemOnc is committed to improving our service to you

Stephen Devereux

There has been a multitude of novel, exciting therapies within the field of chronic lymphocytic leukemia (CLL), explains Stephen Devereux, FRCP, FRCPath, PhD, of King’s College Hospital NHS Foundation Trust, London, UK. At the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK, Prof. Devereux discusses the CLARITY trial (ISCRTN13751862), exploring a combination of ibrutinib and venetoclax, and the promise that this may in the future result in a curative therapy for certain patients.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter